Study explores patient-reported outcomes for UGN-102 in NMIBC

Video

“What we did find is that UGN-102 did not cause decrements in patient-reported urinary symptoms, bloating, flatulence, or malaise at the primary trial end point of 3 months,” says Angela M. Stover, PhD.

In this video, Angela M. Stover, PhD, discusses the rationale and notable findings from the Journal of Urology study, “Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer,” for which she served as a study author. Stover is an assistant professor of health policy and management at the University of North Carolina, Chapel Hill.

Related Videos
Samuel L. Washington III, MD, answers a question during a Zoom video interview
blurred image of a clinic hallway
Dr. Kyle A. Richards in an interview with Urology Times
3d rendered illustration - bladder cancer | Image Credit: © SciePro - stock.adobe.com
stethoscope on laptop keyboard
Randie White, MD, answers a question during a Zoom video interview
Udit Singhal, MD, answers a question during a Zoom video interview
Hospital hallway | Image Credit: © Paolese - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.